All patients included in the French ART Registry (rheumatoid arthritis and anti-TNF) and participating to the e-cohort.  Inclusion Criteria:  Adult patients with RA, Patient in whom the specialist physician decides to start treatment with an anti-TNF drug, regardless of the treatment line and regardless of the anti-TNF, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market Clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription  Exclusion Criteria:  Patient already treated by the same anti-TNF in the past (same drug)